Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643826 | 0.80 | USP2 (0.39) | HSD17B10SMN1; SMN2USP2HSD11B1EPHX2 | |
| SCHEMBL3279795 | 0.78 | — | — | |
| SCHEMBL21408164 | 0.77 | HSD17B10 (0.33) | HSD17B10SMN1; SMN2USP2EPHX2HPGD | |
| SCHEMBL21408122 | 0.76 | USP2 (0.39) | HSD17B10SMN1; SMN2USP2HSD11B1EPHX2 | |
| SCHEMBL16224365 | 0.75 | USP2 (0.38) | HSD17B10SMN1; SMN2USP2EPHX2HPGD | |
| SCHEMBL31752492 | 0.75 | CHRM2 (0.36) | HSD17B10SMN1; SMN2USP2EPHX2HPGD | |
| SCHEMBL31066446 | 0.74 | TGM2 (0.33) | HSD17B10SMN1; SMN2USP2EPHX2HPGD | |
| SCHEMBL21408125 | 0.74 | ACACB (0.40) | HSD17B10SMN1; SMN2USP2HPGDCHRM2 | |
| SCHEMBL17632173 | 0.73 | EPHX2 (0.35) | HSD17B10SMN1; SMN2USP2NPC1EPHX2 | |
| SCHEMBL15024510 | 0.73 | JAK2 (0.36) | HSD17B10SMN1; SMN2USP2EPHX2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | AR, FSHR, NR5A1 | HSD17B10 475/4885SMN1; SMN2 3154/4885USP2 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.